Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria

Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria. There is uncertainty whether the pharmacokinetic properties of primaquine are altered significantly in childhood or not. ABSTRACT Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria. There is uncertainty whether the pharmacokinetic properties of primaquine are altered significantly in childhood or not. Patients with uncomplicated P. vivax malaria and with normal glucose-6-phosphate dehydrogenase were randomized to receive either chloroquine (25 mg base/kg of body weight) or dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine, given either as 0.5 mg base/kg/day for 14 days or 1 mg/kg/day for 7 days. Predose day 7 venous plasma concentrations of chloroquine, desethylchloroquine, piperaquine, primaquine, and carboxyprimaquine were measured. Methemoglobin levels were measured at frequent intervals. Day 7 primaquine and carboxyprimaquine concentrations were available for 641 patients. After adjustment for the milligram-per-kilogram primaquine daily dose, day of sampling, partner drug, and fever clearance, there was a significant nonlinear relationship between age and trough primaquine and carboxyprimaquine concentrations and daily methemoglobin levels. Compared to adults 30 years of age, children 5 years of age had trough primaquine concentrations that were 0.53 (95% confidence interval [CI], 0.39 to 0.73)-fold lower, trough carboxyprimaquine concentrations that were 0.45 (95% CI, 0.35 to 0.55)-fold lower, and day 7 methemoglobin levels that were 0.87 (95% CI, 0.58 to 1.27)-fold lower. Increasing plasma concentrations of piperaquine and chloroquine and poor metabolizer CYP 2D6 alleles were associated with higher day 7 primaquine and carboxyprimaquine plasma concentrations. Higher blood methemoglobin concentrations were associated with a lower risk of recurrence. Young children have lower primaquine and carboxyprimaquine exposures and lower levels of methemoglobinemia than adults. Young children may need higher weight-adjusted primaquine doses than adults. (This study has been registered at ClinicalTrials.gov under identifier NCT01640574.)

[1]  S. Karande,et al.  Evaluation of pharmacokinetics of single-dose primaquine in undernourished versus normally nourished children diagnosed with Plasmodium vivax malaria in Mumbai , 2021, Journal of postgraduate medicine.

[2]  R. Commons,et al.  Doses of primaquine administered to children with Plasmodium vivax according to an age-based dose regimen , 2020, Pathogens and global health.

[3]  N. Waters,et al.  Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with Plasmodium vivax , 2020, The American journal of tropical medicine and hygiene.

[4]  M. Relling,et al.  Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group , 2019, Clinical and translational science.

[5]  R. Price,et al.  Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial , 2019, The Lancet.

[6]  J. Baird,et al.  8-Aminoquinoline Therapy for Latent Malaria , 2019, Clinical Microbiology Reviews.

[7]  Alex B. Miller,et al.  Antimalarial activity of primaquine operates via a two-step biochemical relay , 2019, Nature Communications.

[8]  P. Sachs,et al.  SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells , 2019, Nature Communications.

[9]  N. Day,et al.  High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC–MS/MS , 2019, Bioanalysis.

[10]  F. Nosten,et al.  Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study , 2018, Malaria Journal.

[11]  H. Win,et al.  Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  B. Tekwani,et al.  Metabolism of primaquine in normal human volunteers: investigation of phase I and phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry , 2018, Malaria Journal.

[13]  I. Elyazar,et al.  Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria , 2018, JAMA network open.

[14]  T. Bousema,et al.  Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children , 2017, Antimicrobial Agents and Chemotherapy.

[15]  Sue J Lee,et al.  Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects , 2014, Antimicrobial Agents and Chemotherapy.

[16]  L. Seidlein,et al.  Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis , 2014, The Lancet. Infectious diseases.

[17]  Sue J Lee,et al.  Pharmacokinetic Interactions between Primaquine and Chloroquine , 2014, Antimicrobial Agents and Chemotherapy.

[18]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[19]  P. Siba,et al.  Pharmacokinetic Properties of Single-Dose Primaquine in Papua New Guinean Children: Feasibility of Abbreviated High-Dose Regimens for Radical Cure of Vivax Malaria , 2013, Antimicrobial Agents and Chemotherapy.

[20]  D. Caridha,et al.  The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 , 2013, Malaria Journal.

[21]  Joseph McGraw,et al.  Cytochrome P450 variations in different ethnic populations , 2012, Expert opinion on drug metabolism & toxicology.

[22]  Dale Hattis,et al.  Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[23]  F. Nosten,et al.  Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria , 2008, European Journal of Clinical Pharmacology.

[24]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[25]  J. Umbreit Methemoglobin—It's not just blue: A concise review , 2007, American journal of hematology.

[26]  M. Wong,et al.  Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. , 2005, BioTechniques.

[27]  N. White,et al.  Treatment of vivax malaria on the western border of Thailand. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  R. J. Dern,et al.  Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. , 1955, The Journal of laboratory and clinical medicine.

[29]  A. Kleinman,et al.  Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria , 2013 .

[30]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[31]  M. Wong,et al.  Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. , 2005, BioTechniques.